Still, the timing of COVID-19 treatment is crucial for immunomodulatory approaches like e.g. the widely accepted anti-IL-6 antibody tocilizumab41, and needs to be carefully evaluated also for haemoadsorption. Here, IL6 is linked to COVID-19.